More recently, this group designed a clinically applicable self-inactivating (SIN) lentiviral vector containing the human RPS19 driven by the human EFS promoter for the clinical development of gene therapy for RPS19-deficient DBA patients. This evidence concerns the gene RPS19 and Diamond-Blackfan anemia.